Background: Conventional therapy against acute pediatric cardiopulmonary failure (APCPF) caused by a variety of disease entities remains unsatisfactory with extremely high morbidity and mortality. For refractory APCPF, extracorporeal membrane oxygenation (ECMO) is one of the last resorts.
D
espite advanced pharmacological regimens and the state-of-the-art equipment available, acute pediatric cardiopulmonary failure (APCPF) resulting from various diseases such as acute fulminant myocarditis (AFM), congenital diaphragmatic hernia (CDH), or acute respiratory distress syndrome (ARDS) remains an important cause of morbidity and mortality in the pediatric intensive care units. [1] [2] [3] [4] [5] [6] [7] Therefore, a safe and effective therapeutic strategy for patients with APCPF, especially when conservative medical treatment is inadequate, is of utmost importance for pediatricians.
Extracorporeal membrane oxygenation (ECMO) has been utilized for several decades as a rescue therapy for pediatric CDH, acute myocardial failure, or ARDS refractory to conventional medical therapy. [8] [9] [10] [11] [12] [13] However, the reported promising outcomes highly rely on appropriate patient selection and appropriate disease setting. [8] [9] [10] [11] [12] [13] [14] On the other hand, the clinical outcome of routine use of ECMO support for patients with unselected causes of APCPFs at a single center has been not reported. Since such information is essential in guiding the use of ECMO for APCPF, this study reported the routine application of ECMO support at a single pediatric center in focusing on various disease entities causing APCPF.
METHODS
This was an observational study. The Institutional Review Committee on Human Research at our institution approved the whole study protocol [institutional review board (IRB) number: 100-0407B]. At our hospital, all pediatric patients with APCPF are considered eligible for ECMO support since August 2006. We reviewed our database on all consecutive pediatric patients with a diagnosis of APCPF having received ECMO at Kaohsiung Chang Gung Memorial Hospital Children's Medical Center between August 2006 and May 2011. Totally 22 pediatric patients were prospectively included. The etiologies of APCPF are listed in Table 1 . Informed consent was obtained from each study subject.
Indication for ECMO support and the assess route for ECMO implantation
In Kaohsiung Chang Gung Memorial Hospital, the indications for ECMO implantation included: (1) cardiogenic shock of all etiologies for which stable hemodynamics could not be maintained by conventional therapy and maximal dosage of inotropic agent and (2) severe respiratory failure for which arterial oxygen saturation could not be maintained by mechanical ventilatory support (i.e., PaO 2 < 60 mmHg) and conventional medication with or without hypotension/shock.
For patients with body weight (BW) less than 25 kg, the cervical approach (carotid artery and jugular vein) was utilized for ECMO implantation, whereas femoral approach was adopted for those with BW over 25 kg.
ECMO installation and echocardiographic study
Either veno-venous (VV) or veno-arterial (VA) mode of ECMO was used in the current study. ECMO was inserted either in the operating room or in the pediatric intensive care unit. Initially, 100 units/kg of heparin was given to each patient just before ECMO implementation, followed by a continuous maintenance dose to keep the ACT around 160-220 s.
For ECMO operation in patients with shock, inotropic support was kept to a minimum to maintain mean arterial blood pressures of 40 mmHg for newborn, 50 mmHg for child, and 60 mmHg for adolescent. Flow rates were adjusted according to the hemodynamic status to maintain an SVO2 >60% and urine output >1 mL/kg/h. Normothermia was maintained in all patients.
Prior to ECMO support, echocardiography was used to evaluate ventricular function, i.e., left ventricular ejection 
Management of ECMO
A centrifugal pump and a heparin-bound hollow-fiber microporous membrane oxygenator (50% of patients with Terumo, Asitaka, Japan; another 50% of patients with Medtronic Co., Minneapollis, USA) were utilized. The entire ECMO system and all instruments for vascular assess were available and put on a mobile cart to facilitate transportation to the operating room or pediatric intensive care unit.
For femoral VA mode, the tip of the arterial cannula was estimated to reside at the aorto-iliac junction, whereas the tip of the venous cannula was set at the junction of the inferior vena cava and the right atrium junction. The positions of the cannulas were confirmed radiologically. A catheter was placed for antegrade reperfusion if distal limb perfusion was inadequate.
The carotid artery approach was utilized if patient's BW was <25 kg. Additionally, the cannula size to be selected for the carotid artery was (1) 15.5 French (Fr) for BW ≥20 and < 25 kg, (2) 12.0 Fr for BW ≥ 10 and < 20 kg, and (3) 10.0 Fr for BW < 10 kg.
For neck VA mode, the tip of the arterial cannula was advanced to the junction of innominate artery and ascending aorta, whereas the tip of the venous cannula was set at the middle chamber of right atrium. For neck VV mode, the tip of the double-lumen cannula was set at the junction between right atrium and inferior vena cava. The positions of the cannulas were radiologically and echocardiographically confirmed.
The circuit, including pump head and oxygenator, was replaced under certain conditions, including: (1) a marked plasma leak, (2) hemoglobinuria, and/or (3) blood clot formation in the circuit system.
ECMO weaning protocol
The possibility of weaning from ECMO was evaluated in all patients after 72 h of support. Inotropic agent was tapered carefully in patients with shock after stabilization of general and hemodynamic status together with evidence of improvement in left ventricular contractility (>40% of LVEF). Oxygen saturation was continuously monitored until the mixed venous oxygen saturation was ≥70%. In the absence of deterioration in hemodynamic status, pump flow was reduced gradually to 500 mL/min. Finally, ECMO was withdrawn for persistent stability of the patient's hemodynamic status.
For patients with acute respiratory failure without shock, weaning from ECMO was considered if arterial O 2 saturation was >90%. First, the ECMO oxygenator's fraction of oxygenation (%) (FiO 2 ) was slowly reduced to 21% (i.e., the room air O 2 fraction). If the monitor still showed an arterial O 2 saturation >90%, then the pump blood flow was decreased gradually to 500 mL/min. Finally, ECMO was withdrawn when patient's hemodynamic status and arterial O 2 saturation were found to be stable.
Successful weaning was defined as a survival for more than 72 h after successful cessation of ECMO support. Survival was defined as weaning from ECMO, followed by continued survival till hospital discharge.
Laboratory findings and data collection
For the purpose of this study, all patients undergoing ECMO support were prospectively recruited. Detailed in-hospital data including age, gender, diagnostic criteria, medical treatment prior to ECMO deployment, ECMO-related variables, clinical and hemodynamic condition on admission, laboratory and echocardiographic findings, results of imaging studies, in-hospital adverse events, and in-hospital mortality were obtained. These data were collected prospectively and entered into a digital database.
Statistical analysis
Data were expressed as mean ± SD. Continuous data were analyzed by Wilcoxon rank sum test, while categorical data were analyzed using Fisher's exact test. Statistical analysis was performed using SAS statistical software for Windows version 8.2 (SAS institute, Cary, NC, USA). A p value of < 0.05 was considered statistically significant. Table 1 shows the baseline characteristics and etiologies of APCPF in the 22 study patients. The mean age was 7 years without significant difference between survival group and mortality group. The prevalence of male gender, cardiac arrest, and complete atrio-ventricular block, as well as anthropometric and hemodynamic data including body weight, height, pre-ECMO systolic and diastolic blood pressure were also similar between the two groups. However, the incidence of ventricular tachycardia/ventricular fibrillation was significantly higher in the survival group than that in the mortality group. Three patients experienced intracranial hemorrhage during hospitalization. One was caused by H1N1 infection and another suffered from ARDS associated with hypertension, while the etiology of the third patient was undetermined. Nevertheless, the incidence of this complication did not differ between both groups.
RESULTS

The baseline characteristics of study patients
Of all etiologies of APCPF in the study patients [ Table 1 ], Ying-Jui Lin, et al. ECMO for pediatric cardiopulmonary failure AFM and ARDS were the most common. On the other hand, diabetic ketone acidosis complicated by pulmonary edema and brain herniation, and long QT syndrome with ventricular fibrillation and cardiogenic shock refractory to conventional medical treatment had the lowest incidence. Two patients with brain herniation due to intracranial hemorrhage had clear consciousness prior to ECMO implantation. The prevalence of disease entities causing APCPF did not differ between patients who survived and those who did not. Besides, the mean LVEF of the study patients prior to ECMO support was relatively low (45.7%) compared to that of normal controls (≥60.0%), but it showed no difference between both groups of the patients. However, the LVEF was significantly lower in myocardial failure group than in respiratory failure group (33.2 ± 8.4 vs. 57.2 ± 16.3, p < 0.001).
Utilization of mechanical assisting devices and laboratory findings Table 2 shows the incidence of utilizing different assisting mechanical devices in the 22 patients and their important laboratory findings. Up to 90% of the patients experienced acute respiratory failure with requirement of mechanical ventilatory support prior to ECMO implementation. This finding implicated that the majority of our patients were in an extremely unstable condition.
In our series, the indications for intra-aortic balloon pump IABP support included pulseless electrical activity, asystole, or failure of aortic valve opening confirmed by transthoraxic echocardiography after implementation of ECMO. Four patients with AFM fit these criteria and received the IABP support. The incidence of IABP support did not differ between the survival group and the mortality group. More than 27% of our patients required temporary hemodialysis due to acute renal failure. The incidence of hemodialysis did not differ between survival group and mortality group. Moreover, the incidences of utilizing nitric oxide and high frequency ventilation (HFV) mode as well as the requirement for distal limb perfusion were similar between the two groups. Furthermore, the incidence of temporary pacemaker implantation due to complete heart block was similar between the survival group and the mortality group.
Parameters for laboratory studies prior to ECMO support included white blood cell count, blood sugar, arterial blood gas (i.e. pH value, BE, CO 2 , HCO 3 − , lactic acid, and % O 2 saturation), liver enzymes, and creatine phosphokinase. Except for pH value and % of arterial O 2 saturation which were found to be significantly lower in the mortality group than in survival group, all of the other parameters [ Table 2 ] did not differ between the two groups.
Extremely elevated serum levels of creatine phosphokinase, glutamate oxaloacetate transaminase (GOT) and glutamic pyruvic transaminase (GPT) were observed in the period of ECMO support. In addition, creatinine level was also notably increased during ECMO. Nevertheless, the fluctuations in these biochemical parameters did not differ between the two groups. However, the peak level of creatinine was significantly higher than initial creatinine level (i.e., prior to ECMO implantation) (p < 0.001).
ECMO procedure, results, and outcomes [Table 3]
The successful rate of ECMO implantation was 100%. The VA mode was most frequently used in the current study. Moreover, the incidences of utilizing VA mode and VV mode did not differ between the survival group and the mortality group. Femoral (VA) and neck (carotid artery and internal jugular vein) approaches were the two most common access routes in our series. Post ECMO ligation of carotid artery was performed in 27.3% patients who exhibited no neurological complication during clinical follow-up. The duration of ECMO use and hospitalization were similar between both groups of the patients. The rate of successful weaning from ECMO was significantly higher in the survival group compared to that in the mortality group, whereas mortality associated with failure in weaning was significantly lower in the former.
Univariate and multiple stepwise logistic regression analyses of predictors for in-hospital mortality [Table 4]
To determine the predictors for in-hospital mortality, univariate analysis followed by multiple stepwise logistic regression analysis was performed in the current study. The results identified AFM as the only independent predictor of freedom from in-hospital mortality.
DISCUSSION
The clinical implications of this study, which reported a single-center experience of the routine used of ECMO support for APCPF, are multiple. First, despite divergent etiologies of APCPF in our series, AFM and ARDS pre-dominated. Second, the results of our series demonstrated that the in-hospital prognostic outcome was best for AFM patients. Third, survival rate of the whole cohort was 63.6%, which is comparable to that from recent reports. [8, 12, 13, 15] The routine application of EMCO for APCPF at our Children's Center, therefore, achieved a patient outcome comparable to that from other major centers in the world. [8, 12, 13, 15] Although ECMO support in individual disease setting has been well investigated in previous studies, [8] [9] [10] [11] [12] [13] [14] the clinical outcome of ECMO support for a variety of life-threatening situations has not been reported. To the best of our knowledge, this is the first report on the safety, efficacy, and outcome of ECMO support for APCPF of different etiologies based on single-center experience. Of particular importance is that our study not only demonstrated the feasibility of routine ECMO support for patients with APCPF, but also showed a favorable patient survival.
The management of patients with AFM, especially those requiring mechanical circulatory support, remains a formidable challenge for pediatricians. Despite initial successful resuscitation, some survivors eventually required heart transplantation due to refractory pump failure. [11] Previous studies have reported promising outcomes from neonatal ECMO service for AFM with an overall survival and discharge rate reaching 62.5-71%. [11, [16] [17] [18] [19] In our series, AFM was the prevalent etiology of APCPF. The results of our study demonstrated a 100% success rate of cure and discharge for this patient population. Of particular importance is that multivariate analysis demonstrated that AFM was independently predictive of freedom from in-hospital mortality. Accordingly, our result, in addition to reinforcing those from previous studies, [11, [16] [17] [18] [19] supports the use of ECMO for pediatric patients with AFM to improve their prognostic outcome.
In this cohort study, ARDS was the second prevalent etiology of APCPF. In contrast to a 100% in-hospital survival rate in patients with AFM, only 50% of in-hospital survival rate was achieved in patients with ARDS in our study. By contrast, previous studies [12, 15, 20] have reported up to 70% of in-hospital survival rate in patients with ARDS. The relatively low in-hospital survival rate in our patients could probably be explained by the distinctive difference in patient population between the previous studies [12, 15, 20] and our series. While previous studies [12, 15, 20] mainly enrolled neonatal (<1 year) patients or children after open heart surgery with cardiac failure, the majority of our patients (n = 5) were children (>1 year) with etiology of ARDS not related to cardiac disease/cardiac surgery. We also propose that delayed ECMO support may be another reason for the lower in-hospital survival rate in our patients with ARDS as the consultation for ECMO support from non-cardiologists usually took more than 3 days after the diagnosis of ARDS. Hence, the results of our study reinforce the importance of timely referral for ECMO in the clinical setting of ARDS.
Technical challenge and ECMO-related neurological sequelae
In the current study, up to 45.5% of our patients required a cervical approach (carotid artery and internal jugular vein) for ECMO implantation due to small size of femoral artery. Majority of the carotid arteries in these patients, therefore, were subsequently ligated after weaning from ECMO. No carotid artery ligation-related neurological sequelae were observed in our series. Additionally, patients with body weight <15 kg (40.9% of our patients) or age <1 year (18.2% of our patients), who were not recommended for ECMO support, successfully underwent the procedure without complication. Our findings suggest that ECMO support in neonates and infants of small body size could be a safe and feasible life-saving measure. Relevant clinical implication of current study and study limitation Nowadays, the ECMO support, an advanced treatment modality for acute severe cardiopulmonary failure to be permitted in Taiwan, is also widely acceptable in most Asian and Western countries. Additionally, it is suitable not only for the adult but also for pediatric patients. In the present study, the divergent setting of disease entities and the different modes of ECMO to be used as well as small number of sample size, as expected, would preclude the interpretation of statistical significance. Thus, the conclusions are tentative and need to be further verified by large-scale randomized clinical trials.
Although ECMO support in pediatric patients in this clinical setting is particularly important for their survival, the clinical adjustments, including how to select the femoral, carotid cannula, and type of the pump, how to estimate and control the ECMO flow, how to give the fluid and nutrient support, and how to provide mental support for both patients and families are of particular importance for the pediatric physicians and paramedical members.
